

# Cornelius J Clancy

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7901612/cornelius-j-clancy-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114  
papers

4,082  
citations

34  
h-index

63  
g-index

132  
ext. papers

5,642  
ext. citations

5.8  
avg, IF

6.14  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 114 | Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1367-1376   | 11.6 | 607       |
| 113 | Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,  | 5.9  | 245       |
| 112 | Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,   | 5.9  | 239       |
| 111 | Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: Clinical Effectiveness and Evolution of Resistance. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 110-120  | 11.6 | 167       |
| 110 | Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1524-1535   | 14.5 | 149       |
| 109 | Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,  | 5.9  | 130       |
| 108 | Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect?. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 2736-2743   | 11.6 | 124       |
| 107 | Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum $\beta$ -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR-P. <i>aeruginosa</i> ). <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e169-e183 | 11.6 | 105       |
| 106 | <i>Candida albicans</i> Pathogenesis: Fitting within the Host-Microbe Damage Response Framework. <i>Infection and Immunity</i> , <b>2016</b> , 84, 2724-39   | 3.7  | 101       |
| 105 | Effects of <i>Klebsiella pneumoniae</i> carbapenemase subtypes, extended-spectrum $\beta$ -lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant <i>K. pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 5793-7   | 5.9  | 87        |
| 104 | Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,   | 5.9  | 86        |
| 103 | Carbapenem-resistant <i>Klebsiella pneumoniae</i> strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 4443-51  | 5.9  | 82        |
| 102 | Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153247   | 3.7  | 80        |
| 101 | Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, S30-S35  | 11.6 | 78        |
| 100 | Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, S52-S52  | 1    | 78        |
| 99  | Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, S297-S297   | 1    | 78        |
| 98  | 247. Sustaining Excellence of Care During a Fluid Shortage: Snapshot of Antibiotic Mitigation Strategies Following Hurricane Maria. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S105-S105   | 1    | 78        |

|    |  |      |    |
|----|--|------|----|
| 97 | Abdominal candidiasis is a hidden reservoir of echinocandin resistance. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 7601-5  | 5.9  | 77 |
| 96 | Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Carbapenemase-Producing : A Case Report and Review of Literature. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx101  | 1    | 74 |
| 95 | Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3227-31   | 5.9  | 71 |
| 94 | Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from $\beta$ -Lactamase Protein Engineering. <i>MBio</i> , <b>2017</b> , 8,   | 7.8  | 68 |
| 93 | Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible <i>Klebsiella pneumoniae</i> Isolates with Variant KPC-3 Carbapenemases. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,   | 5.9  | 63 |
| 92 | Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum $\beta$ -Lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR-P. <i>aeruginosa</i> ). <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 1100-1111 | 11.6 | 58 |
| 91 | T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, iv2-iv5   | 5.1  | 51 |
| 90 | Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,   | 5.9  | 51 |
| 89 | Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,  | 5.9  | 48 |
| 88 | Rapid Detection of FKS-Associated Echinocandin Resistance in <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 6573-6577  | 5.9  | 47 |
| 87 | Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 667-671   | 11.6 | 42 |
| 86 | Effects of KPC Variant and Porin Genotype on the Activity of Meropenem-Vaborbactam against Carbapenem-Resistant. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,  | 5.9  | 42 |
| 85 | Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz344  | 1    | 38 |
| 84 | Rate of FKS Mutations among Consecutive <i>Candida</i> Isolates Causing Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 7465-70  | 5.9  | 36 |
| 83 | PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates. <i>JAC-Antimicrobial Resistance</i> , <b>2020</b> , 2, dlaa049   | 2.9  | 36 |
| 82 | Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against <i>Klebsiella pneumoniae</i> Carbapenemase- and Extended-Spectrum- $\beta$ -Lactamase-Producing Enterobacter Species. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 5208-14          | 5.9  | 34 |
| 81 | Delinking CARD9 and IL-17: CARD9 Protects against <i>Candida tropicalis</i> Infection through a TNF- $\beta$ -Dependent, IL-17-Independent Mechanism. <i>Journal of Immunology</i> , <b>2015</b> , 195, 3781-92  | 5.3  | 32 |
| 80 | Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing <i>Klebsiella pneumoniae</i> strains with various ompK36 genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 3521-5  | 5.9  | 32 |

|    |  |      |    |
|----|--|------|----|
| 79 | Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa. <i>Journal of Clinical Microbiology</i> , <b>2018</b> , 56,  | 9.7  | 32 |
| 78 | Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3187-92  | 5.9  | 31 |
| 77 | Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , <b>2021</b> , 47, 819-834   | 14.5 | 30 |
| 76 | Candida glabrata intra-abdominal candidiasis is characterized by persistence within the peritoneal cavity and abscesses. <i>Infection and Immunity</i> , <b>2014</b> , 82, 3015-22   | 3.7  | 29 |
| 75 | Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,  | 5.9  | 29 |
| 74 | Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab065  | 1    | 28 |
| 73 | Infectious Diseases Society of America Guidance on the Treatment of AmpC $\beta$ -lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,         | 11.6 | 27 |
| 72 | Invasive mould disease in fatal COVID-19: a systematic review of autopsies. <i>Lancet Microbe</i> , <b>2021</b> , 2, e405-e414   | 22.2 | 27 |
| 71 | Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 1797-801 | 5.9  | 24 |
| 70 | Impact of the Coronavirus Disease 2019 Pandemic on Outpatient Antibiotic Prescriptions in the United States. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa575  | 1    | 23 |
| 69 | Spontaneous Mutational Frequency and Mutation Rates Vary by Echinocandin Agent against. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,   | 5.9  | 21 |
| 68 | Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 416-426  | 11.6 | 19 |
| 67 | How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 850-853  | 11.6 | 19 |
| 66 | Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,   | 5.9  | 18 |
| 65 | Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> ,  | 5.9  | 17 |
| 64 | Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 1068-74   | 2.9  | 16 |
| 63 | KPC-producing Klebsiella pneumoniae strains that harbor AAC(6)IIb exhibit intermediate resistance to amikacin. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 7597-600   | 5.9  | 16 |
| 62 | Coordination of Candida albicans Invasion and Infection Functions by Phosphoglycerol Phosphatase Rhr2. <i>Pathogens</i> , <b>2015</b> , 4, 573-89  | 4.5  | 13 |

|    |  |      |    |
|----|--|------|----|
| 61 | Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3558-62   | 5.9  | 13 |
| 60 | Highly Dynamic and Specific Phosphatidylinositol 4,5-Bisphosphate, Septin, and Cell Wall Integrity Pathway Responses Correlate with Caspofungin Activity against <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3591-600                         | 5.9  | 12 |
| 59 | Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,   | 5.9  | 11 |
| 58 | Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clinical Practice Guidelines on the Treatment of <i>Clostridium difficile</i> Infections in the United States. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 1944-1949 | 11.6 | 11 |
| 57 | Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000-2017. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e4521-e4530  | 11.6 | 10 |
| 56 | Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,  | 5.9  | 9  |
| 55 | Susceptibility of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65,  | 5.9  | 9  |
| 54 | Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of in a Hollow Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,   | 5.9  | 8  |
| 53 | An Introduction to the Medically Important <i>Candida</i> Species9-25  |      | 8  |
| 52 | Adhesins in Opportunistic Fungal Pathogens243-P2   |      | 5  |
| 51 | The Epidemiology of Invasive Candidiasis449-480  |      | 5  |
| 50 | Rapid diagnosis of invasive candidiasis: ready for prime-time?. <i>Current Opinion in Infectious Diseases</i> , <b>2019</b> , 32, 546-552  | 5.4  | 5  |
| 49 | Invasive Mould Disease in Fatal COVID-19: A Systematic Review of Autopsies   |      | 5  |
| 48 | The Cell Wall: Glycoproteins, Remodeling, and Regulation195-223  |      | 4  |
| 47 | Salivary Histatins: Structure, Function, and Mechanisms of Antifungal Activity185-194  |      | 3  |
| 46 | Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use343-371  |      | 3  |
| 45 | Genetic diversity of clinical and environmental Mucorales isolates obtained from an investigation of mucormycosis cases among solid organ transplant recipients. <i>Microbial Genomics</i> , <b>2020</b> , 6,  | 4.4  | 3  |
| 44 | It's worse than we thought: the US market for novel Gram-negative antibiotics. <i>Lancet Infectious Diseases</i> , <b>2020</b> , 20, 1009-1010   | 25.5 | 3  |

|    |  |      |   |
|----|--|------|---|
| 43 | Mucosal Immunity to <i>Candida albicans</i> 137-154  |      | 2 |
| 42 | Insights in Antifungal Drug Discovery387-401   |      | 2 |
| 41 | Invasive Pulmonary Aspergillosis Complicating Noninfluenza Respiratory Viral Infections in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab478   | 1    | 2 |
| 40 | Molecular epidemiology, natural history and long-term outcomes of multi-drug resistant Enterobacterales colonization and infections among solid organ transplant recipients. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,       | 11.6 | 2 |
| 39 | Suprapubic catheter placement improves antimicrobial stewardship among Veterans Affairs nursing care facility residents. <i>American Journal of Infection Control</i> , <b>2020</b> , 48, 1264-1266                                    | 3.8  | 1 |
| 38 | PCR-Based Methods for the Diagnosis of Invasive Candidiasis: Are They Ready for Use in the Clinic?. <i>Current Fungal Infection Reports</i> , <b>2018</b> , 12, 71-77  | 1.4  | 1 |
| 37 | Stress Responses in <i>Candida</i> 225-242   |      | 1 |
| 36 | Gene Expression during the Distinct Stages of Candidiasis283-298   |      | 1 |
| 35 | The Impact of Antifungal Drug Resistance in the Clinic373-385  |      | 1 |
| 34 | Mucosal Candidiasis417-427   |      | 1 |
| 33 | Systemic Candidiasis: Candidemia and Deep-Organ Infections429-441  |      | 1 |
| 32 | Cell Cycle and Growth Control in <i>Candida</i> Species101-124   |      | 1 |
| 31 | <i>Candida</i> : What Should Clinicians and Scientists Be Talking About?1-8  |      | 1 |
| 30 | Back to the Future: <i>Candida</i> Mitochondria and Energetics331-341  |      | 1 |
| 29 | Sequence type-258 carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates in which ceftazidime-avibactam resistance emerged are not hypermutators. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2020</b> , 96, 114954 | 2.9  | 1 |
| 28 | Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofaa656   | 1    | 1 |
| 27 | Reply to Turner. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 2065-2066   | 11.6 | 1 |
| 26 | Fungal infections in lung transplantation.. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 6695-6707   | 2.6  | 0 |

|    |   |         |   |
|----|---|---------|---|
| 25 | Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab441                                | 1       | 0 |
| 24 | Exploratory Cost-Effectiveness Analysis for Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections: Is Linezolid or Daptomycin Favored Over Vancomycin?. <i>Clinical Drug Investigation</i> , <b>2021</b> , 41, 885-894 | 3.2     | 0 |
| 23 | Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak. <i>American Journal of Infection Control</i> , <b>2021</b> , 49, 1237-1241  | 3.8     | 0 |
| 22 | Coronavirus Disease 2019-Associated Pulmonary Aspergillosis: Reframing the Debate.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac081  | 1       | 0 |
| 21 | What Is New in Candida Infections? T2Candida, Antifungal Stewardship, and Candida auris. <i>Current Treatment Options in Infectious Diseases</i> , <b>2020</b> , 12, 1-12   | 1       |   |
| 20 | Discordance Among Antibiotic Prescription Guidelines Reflects a Lack of Clear Best Practices. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofaa571  | 1       |   |
| 19 | Multidrug Resistance Transcriptional Regulatory Networks in Candida   | 403-416 |   |
| 18 | Switching and Mating  | 75-90   |   |
| 17 | Vaccines and Passive Immunity against Candidiasis   | 171-184 |   |
| 16 | The Genetic Code of the Candida CTG Clade   | 45-55   |   |
| 15 | Innate Immunity to Candida Infections   | 155-170 |   |
| 14 | Cool Tools 5: The Candida albicans ORFeome Project  | 505-510 |   |
| 13 | Comparative Genomics of Candida Species   | 27-43   |   |
| 12 | Detection and Clinical Significance of Variability among Candida Isolates   | 91-99   |   |
| 11 | Cool Tools 3: Large-Scale Genetic Interaction Screening in Candida albicans   | 497-500 |   |
| 10 | Cool Tools 4: Imaging Candida Infections in the Live Host   | 501-P1  |   |
| 9  | Encounters with Mammalian Cells: Survival Strategies of Candida Species   | 261-P1  |   |
| 8  | Candida spp. in Microbial Populations and Communities: Molecular Interactions and Biological Importance   | 317-330 |   |

- 7 New Developments in Diagnostics and Management of Invasive Candidiasis 443-448
- 6 Biofilm Formation in *Candida albicans* 299-315
- 5 Genome Instability and DNA Repair 57-P2
- 4 Cool Tools 2: Development of a *Candida albicans* Cell Surface Protein Microarray 489-496
- 3 Immunology of Invasive Candidiasis 125-136
- 2 Transcriptional Profiling Within Biliary Fluid From a Patient With Cholangitis, Before and After Antifungal Treatment and Surgical Drainage. *Open Forum Infectious Diseases*, **2016**, 3, ofw120 1
- 1 Antibacterial Drug Development Trends in the United States from 1980-2019: Agents Active Against Carbapenem-resistant Gram-negative Bacteria as Case Study. *Clinical Infectious Diseases*, **2021**, 72, e437-e438 11.6